Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679236 | 0.83 | ADH1B (0.48) | ADH1BADH1CADH1AADH7MEN1 | |
| SCHEMBL10809223 | 0.80 | EPHX2 (0.52) | ADH1BADH1CADH1AADH7MEN1 | |
| SCHEMBL3374456 | 0.79 | ADH1B (0.52) | ADH1BADH1CADH1AADH7MEN1 | |
| SCHEMBL5985351 | 0.76 | MAOA (0.58) | CHRM2MEN1KMT2A | |
| SCHEMBL7068986 | 0.73 | ALDH1A1 (0.65) | KCNH2OPRM1DRD3DRD2OPRD1 | |
| SCHEMBL6947636 | 0.72 | OPRM1 (0.73) | KCNH2OPRM1DRD3DRD2OPRD1 | |
| SCHEMBL5879246 | 0.72 | OPRM1 (0.73) | KCNH2OPRM1DRD3DRD2OPRD1 | |
| Benzyl Bromide SCHEMBL457700 | 0.72 | TRPA1 (0.58) | KCNH2OPRM1DRD3DRD2OPRD1 | |
| SCHEMBL12540441 | 0.72 | OPRM1 (0.74) | KCNH2OPRM1DRD3DRD2OPRD1 | |
| SCHEMBL9720308 | 0.72 | MAPT (0.58) | KCNH2OPRM1DRD3DRD2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984664-B2 | Tertiary amino compounds having opioid receptor affinity | EURO-CELTIQUE, S.A. (LU) | 2006-01-10 | — | — | US | claimed |
| EP-1244437-A4 | TERTIARY AMINO COMPOUNDS HAVING OPIOID RECEPTOR AFFINITY | EURO CELTIQUE SA (LU) | 2005-02-09 | — | — | EP | claimed |
| EP-1244437-A1 | TERTIARY AMINO COMPOUNDS HAVING OPIOID RECEPTOR AFFINITY | Euro-Celtique, S.A. (LU) | 2002-10-02 | — | — | EP | claimed |
| US-20010041746-A1 | Tertiary amino compounds having opioid receptor affinity | PURDUE PHARMA L.P. | 2001-11-15 | — | — | US | claimed |
| WO-2001039767-A1 | TERTIARY AMINO COMPOUNDS HAVING OPIOID RECEPTOR AFFINITY | EURO-CELTIQUE, S.A. (LU) | 2001-06-07 | — | — | WO | claimed |
| US-20060106114-A1 | Tertiary amino compounds having opioid receptor affinity | EURO-CELTIQUE S.A. (LU) | 2006-05-18 | — | — | US | disclosed |
| US-6984664-B2 | Tertiary amino compounds having opioid receptor affinity | EURO-CELTIQUE, S.A. (LU) | 2006-01-10 | — | — | US | disclosed |
| EP-1244437-A4 | TERTIARY AMINO COMPOUNDS HAVING OPIOID RECEPTOR AFFINITY | EURO CELTIQUE SA (LU) | 2005-02-09 | — | — | EP | disclosed |
| EP-1244437-A1 | TERTIARY AMINO COMPOUNDS HAVING OPIOID RECEPTOR AFFINITY | Euro-Celtique, S.A. (LU) | 2002-10-02 | — | — | EP | disclosed |
| US-20010041746-A1 | Tertiary amino compounds having opioid receptor affinity | PURDUE PHARMA L.P. | 2001-11-15 | — | — | US | disclosed |
| WO-2001039767-A1 | TERTIARY AMINO COMPOUNDS HAVING OPIOID RECEPTOR AFFINITY | EURO-CELTIQUE, S.A. (LU) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041746-A1 | Tertiary amino compounds having opioid receptor affinity | OPRK1, OPRL1, OPRM1 | KCNH2 552/4885OPRM1 3/4885DRD3 114/4885 |
| US-20060106114-A1 | Tertiary amino compounds having opioid receptor affinity | OPRL1, OPRK1, OPRM1 | KCNH2 677/4885OPRM1 3/4885DRD3 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.